Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus FOLFIRI in Metastatic Colorectal Cancer
NCT03880877Phase 2Unknown
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in metastatic colorectal cancer (mCRC), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03880877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03880877.